Table 1

Clinical characteristics of patients undergoing TAVI according to the occurrence of at least moderate post-procedural AR

CharacteristicsAR≥2/4 (n=119)AR<2/4 (n=571)p ValueOR (95% CI)
Age (years)81.1±6.381.4±6.40.72
Male gender68 (57)239 (42)0.0021.85 (1.24 to 2.76)
Weight (kg)74.8±16.273.6±16.20.48
Height (cm)166±11.4166±8.80.37
BMI (kg/m2)28.4±20.226.8±6.80.86
Cardiogenic shock/decompensation42 (35)135 (24)0.011.74 (1.14 to 2.65)
Pulmonary hypertension85 (72)340 (61)0.021.67 (1.08 to 2.59)
Atrial fibrillation33 (28)124 (22)0.171.37 (0.88 to 2.15)
Diabetes mellitus38 (32)201 (35)0.460.85 (0.56 to 1.30)
Previous MI23 (20)90 (16)0.321.30 (0.78 to 2.16)
Coronary artery disease75 (64)336 (59)0.40
 Three-vessel disease42 (36)138 (24)0.011.71 (1.12 to 2.62)
 Left main disease6 (5.1)33 (5.9)0.740.86 (0.35 to 2.11)
Previous cardiac surgery38 (32)125 (22)0.021.66 (1.08 to 2.56)
Peripheral arterial disease24 (20)94 (17)0.341.27 (0.77 to 2.09)
Aortic aneurysm6 (5)10 (1.8)0.032.96 (1.05 to 8.30)
Previous stroke12 (10)43 (7.6)0.351.37 (0.70 to 2.68)
Renal failure*62 (56)360 (63)0.020.64 (0.43 to 0.95)
COPD35 (29)137 (24)0.231.31 (0.85 to 2.03)
Logistic Euroscore (%)24±15.619.6±12.50.01
ASA physical status class
 1=normal healthy patient0 (0)13 (2.3)0.09
 2=patient with mild systemic disease38 (32)180 (32)0.961.01 (0.66 to 1.55)
 3=patient with severe systemic disease (limits function but is not incapacitating)65 (55)294 (52)0.571.12 (0.75 to 1.67)
 4=patient with severe systemic disease that is a constant threat to life12 (10)71 (13)0.460.78 (0.41 to 1.50)
 5=moribund patient3 (2.5)5 (0.9)0.122.91 (0.69 to 12.35)
NYHA functional class
 0/I1 (0.9)10 (1.8)0.470.48 (0.06 to 3.78)
 II7 (6)61 (11)0.110.53 (0.23 to 1.18)
 III82 (70)400 (71)0.890.97 (0.63 to 1.50)
 IV27 (23)95 (17)0.111.49 (0.92 to 2.41)
  • Values are n (%) or mean±SD.

  • * Defined as glomerular filtration rate <60 ml/min/1.73 m2.

  • AR, aortic regurgitation; ASA, American Society of Anesthesiologists; BMI, body mass index; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NYHA, New York Heart Association; TAVI, transcatheter aortic valve implantation.